Related Experiment Video
Updated: Jul 17, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Severe psoriasis treated with a new macrolide: everolimus
E Frigerio1, M D Colombo, C Franchi
1Institute of Dermatology, Ospedale Galeazzi, University of Milan, Via R Galeazzi 4, 20161 Milan, Italy.
The British Journal of Dermatology
|January 17, 2007
Summary
Severe psoriasis, often resistant to standard treatments, was managed using everolimus, a novel immunosuppressant. This rapamycin derivative was combined with low-dose ciclosporin, offering a new therapeutic approach for difficult psoriasis cases.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Psoriasis is a chronic, immune-mediated skin condition with relapsing episodes.
- Severe psoriasis forms often resist conventional treatments, posing management challenges.
- Everolimus, a rapamycin-derived macrolide, possesses immunosuppressive and antiproliferative properties.
Observation:
- A patient with severe, treatment-refractory psoriasis was treated with everolimus.
- The treatment regimen involved combining everolimus with subtherapeutic doses of ciclosporin.
- Ciclosporin is a calcineurin inhibitor with a distinct yet complementary mechanism to everolimus.
Findings:
- The combination therapy aimed to leverage the complementary mechanisms of everolimus and ciclosporin.
- This approach explored a novel therapeutic strategy for severe psoriasis.
- The study details the treatment of a specific patient case.
Implications:
- This case suggests a potential new treatment avenue for severe, refractory psoriasis.
- Combining everolimus with low-dose ciclosporin may offer an alternative for patients unresponsive to traditional therapies.
- Further research is warranted to evaluate the efficacy and safety of this combination therapy in a broader psoriasis population.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...